Anabolic-androgenic steroids for alcoholic liver disease

Cochrane Database of Systematic Reviews

Volumn 2009, Issue 1, 2006, Pages

  Rambaldi, Andrea ^a   Gluud, Christian ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; ANDROGEN;

ALCOHOL LIVER DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

ANABOLIC AGENTS; ANDROGENS; HUMANS; LIVER DISEASES, ALCOHOLIC; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 39049193725     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003045.pub2     Document Type: Review

References (101)

1. Bonkovsky HL, Fiellin DA, Smith GS, Slaker DP, Simon D, Galambos JT. A randomized, controlled trial of treatment of alcoholic hepatitis with parenteral nutrition and oxandrolone. I. Short-term effects on liver function. The American Journal of Gastroenterology 1991;86(9):1200-8.
2. Bonkovsky HL, Fiellin DA, Smith GS, Slaker DP, Simon D, Galambos JT. Treatment of alcoholic hepatitis with parenteral nutrition and oxandrolone: a randomized controlled trial. I. Short-term effects on liver function. Hepatology 1990;12(4):870.
3. Bonkovsky HL, Jafri IH, Singh RH, Cotsonis GA, Slaker DP. Treatment of alcoholic hepatitis with parenteral nutrition and oxandrolone: a randomized controlled trial. II. Effects on nitrogen metabolism. Hepatology 1990;12(4):978.
4. Bonkovsky HL, Singh RH, Jafri IH, Fiellin DA, Smith GS, Simon D, et al. A randomized, controlled trial of treatment of alcoholic hepatitis with parenteral nutrition and oxandrolone. II. Short-term effects on nitrogen metabolism, metabolic balance, and nutrition. The American Journal of Gastroenterology 1991;86(9):1209-18.
5. Becker U, Gluud C, Bennett P, the Copenhagen Study Group for Liver Diseases. The effect of oral testosterone on serum TBG levels in alcoholic cirrhotic men. Liver 1988;8:219-24.
6. Gluud C, Christoffersen P, Eriksen J, Wantzin P, Knudsen BB, the Copenhagen Study Group for Liver Diseases. No effect of long-term oral testosterone treatment on liver morphology in men with alcoholic cirrhosis. The American Journal of Gastroenterology 1987;82(7):660-4.
7. Gluud C, Henriksen JH, the Copenhagen Study Group for Liver Diseases. Liver haemodynamics and function in alcoholic cirrhosis. Relation to testosterone treatment and ethanol consumption. Journal of Hepatology 1987;4:168-73.
8. Gluud C, Wantzin P, Eriksen J, the Copenhagen Study Group for Liver Diseases. No effect of oral testosterone treatment on sexual dysfunction in alcoholic cirrhotic men. Gastroenterology 1988;95(6):1582-7. [PMID 3053314]
9. Gluud C, the Copenhagen Study Group for Liver Diseases. Effect of testosterone treatment in men with alcoholic cirrhosis. Journal of Hepatology 1985;Suppl 1:S59.
10. Gluud C, the Copenhagen Study Group for Liver Diseases. Serum concentrations in men with alcoholic cirrhosis: background for variation. Metabolism 1987;36(4):373-8.
11. The Copenhagen Study Group for Liver Diseases. Testosterone treatment of men with alcoholic cirrhosis: a double-blind study. Hepatology 1986;6(5):807-13.
12. Fenster LF. The nonefficacy of short-term anabolic steroid therapy in alcoholic liver disease. Annals of Internal Medicine 1966;65(4):738-44.
13. Mendenhall CL, Goldenberg S. Risk factors and therapy in alcoholic hepatitis (AH). Gastroenterology 1977;72(5):1100.
14. Mendenhall CL, Anderson S, Garcia-Pont P, Goldberg S, Kiernan T, Seeff LB, et al. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. New England Journal of Medicine 1984;311:1464-70.
15. Mendenhall CL, Moritz TE, Roselle GA, Morgan TR, Nemchausky BA, Tamburro CH, et al. A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: results of a Department of Veteran Affairs Cooperative Study. Hepatology 1993;17:564-76.
16. Eberhardt G, Mohr J, Oehlert W, Schmidt E, Schmidt FW, Wondrasek P. Controlled study of the therapeutic effect of B-vitamins and anabolic steroid in chronic hepatitis [Kontrollierte studie zur therapeutischen wirkung von B vitaminen und einem anabolen steroid bei chronischer hepatitis]. Deutsche Medizinsche Wochenschrift 1975;100:2074-82. [MEDLINE: 76021845]
17. Fiegel G, Kelling H-W. The influence of high doses of androgen derivates and of corticosteroids on severe parenchymal diseases [Die beeinflussung des schweren leberparenchymschadens unter zufuhr hochdosierter androgenderivate und von corticosteroiden]. Arztliche Forschung 1959;13:574-8.
18. Figueroa RB. Mesterolone in steatosis and cirrhosis of the liver. Acta Hepato Gastroenterologica 1973;20:282-90.
19. Franken FH, Daweke H, Gries EA, Schweinitz HA, Holzgrewe H, Forstmannn U. Long term treatment of chronic liver diseases with prednisone and methandrostenolon [Langzeitbehandlung chronischer lebererkrankungen mit prednison und methandrostenolon]. Deutsche Medizinsche Wochenschrift 1963;88:1979-85.
20. Gill R, Zieve L, Logan G. Severe alcoholic hepatitis improved by combined treatment with prednisolone, testosterone and an amino acid supplement. Hepatology 1984;4(5):26.
21. Girolami M. Treatment of ascitic atrophic cirrhosis of the liver with high dosages of testosterone propionate. Journal of the American Geriatrics Society 1958;6:306-23.
22. Gluud C, Bennett P, Dietrichson O, Johnsen SG, Ranek L, Svendsen LB, et al. Short-term parenteral and peroral testosterone administration in men with alcoholic cirrhosis. Scandinavian Journal of Gastoenterology 1981;16:749-55.
23. Hirayama C, Kimura N, Masuya T. Anabolic steroid effect on hepatic protein synthesis in patients with liver cirrhosis. Digestion 1970;3:41-7.
24. Islam N, Islam A. Testosterone propionate in cirrhosis of the liver. The British Journal of Clinical Practice 1973;27(4):125-8.
25. Jabbari M, Leevy CM. Protein anabolism and fatty liver of the alcoholic. Medicine 1967;46(2):131-9.
26. Kley HK, Strohmeyer G, Krüskemper HL. Effect of testosterone application on hormone concentrations of androgens and estrogens in male patients with cirrhosis of the liver. Gastroenterology 1979;76(2):235-41. [PMID 569612]
27. Knobel H, Becker K. Effect of an anabolic steroid (methenolone enanthate) on the intra-and extravasal albumin pool in liver cirrhosis [Die wirkung eines anabol wirkenden steroids (metenolononanthat) auf den intra-und extravasalen albuminpool bei leberzirrhose]. Zeitschrift für Gastroenterologie 1975;13(6):583-7. [PMID 1224752]
28. Leevy CM. Fatty liver: a study of 270 patients with biopsy proven fatty liver and a review of the literature. Medicine 1962;41:249-76.
29. Lindner H. Long-term therapy of liver cirrhosis with anabolic steroids [Langzeittherapie der leberzirrhose mit anabolen steroiden]. Medizinische Klinik 1967;62:59-63. [PMID 5592142]
30. Mendenhall CL. Anabolic steroid therapy as an adjunct to diet in alcoholic hepatic steatosis. American Journal of Digestive Diseases 1968;13(9):783-91.
31. Mendenhall CL. Augmented release of hepatic triglycerides with anabolic steroids in patients with fatty liver. Digestive Diseases 1974;19(2):122-6.
32. Mendenhall CL, Moritz T, the DVA Coop Study Group 275. Therapy with oxandrolone (OX) and a high calorie supplement improves nutritional status in dempensated alcoholic hepatitis (AH) with moderate proteine calorie malnutrition (PCM). Hepatology 1991;14(4):233A.
33. Mendenhall CL, Moritz TE, Roselle GA, Morgan TR, Nemchausky BA, Tamburro CH, et al. A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: results of a Department of Veteran Affairs Cooperative Study. Hepatology 1993;17:564-76.
34. Mendenhall CL, Moritz TE, Roselle GA, Morgan TR, Nemchausky BA, Tamburro CH, et al. Protein energy malnutrition in severe alcoholic hepatitis: diagnosis and response to treatment. Journal of Parenteral and Enteral Nutrition 1995;19(4):258-65.
35. Mendenhall CL, Roselle GA, Gartside P, Moritz T. Relationship of protein calorie malnutrition to alcoholic liver disease: a reexamination of data from two Veterans Administration Cooperative Studies. Alcoholism, Clinical Experimental Research 1995;19(3):635-41.
36. Mezinskis J, Mendenhall CL, Moritz T, the VA Coop Study Group #275. Improve cognitive function as the result of nutrition therapy for patients with alcoholic hepatitis. Hepatology 1991;14(4):233A.
37. Morgan TR, Haas R, Moritz T, Mendenhall CL, VA Coop Study #275. Does high protein intake increase the risk of hepatic encephalopathy (HE) in patients with alcoholic hepatitis (AH)?. Hepatology 1991;14(4):233A.
38. Morgan TR, Mortitz T, Mendenhall CL. Nutritional therapy for alcoholic hepatitis. VA Cooperative 275 Study Group. Gastroenterology 1992;103(1):357-8.
39. Müting D. Protein metabolism, excretion, and detoxication functions of the liver after long-term treatment of liver cirrhosis with an anabolic substance. American Journal of Digestive Diseases 1965;10:790-5.
40. Puliyel MM, Vyas GP, Mehta GS. Testosterone in the management of cirrhosis of the liver - a controlled study. Australian and New Zealand Journal of Medicine 1977;7:596-9.
41. Rosenak BD, Moser RH, Howell JD. The effect of administration of testosterone propionate on excretion of water in patients with cirrhosis of the liver. Gastroenterology 1950;14:382-5.
42. Rosenak BD, Moser RH, Kilgore B Jr. Treatment of cirrhosis of the liver with testosterone propionate. Gastroenterology 1947;9:695-704.
43. Seifert E, Dittrich H. Therapy of chronic liver diseases with dacomid [Therapie chronischer lebererkrankungen mit dacomid]. Medizinische Klinik 1967;62(27):1055-8. [PMID 4874027]
44. Tamburro C, Leevy CM. Protein clotting factor synthesis in liver disease. Gastroenterology 1967;52:325.
45. Wells R. Prednisolone and testosterone propionate in cirrhosis of the liver. A controlled trial. Lancet 1960;276(7166):1416-9.
46. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119(6):1787-91.
47. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other mis(uses) of baseline data in clinical trials. Lancet 2000;355:1064-9.
48. Becker U. The influence of ethanol and liver disease on sex hormones and hepatic oestrogen receptors in women. Danish Medical Bulletin 1993;40(4):447-59. [PMID 8222764]
49. Bird GL, Prach AT, McMahon AD, Forrest JA, Mills PR, Danesh BJ. Randomised controlled double-blind trial of the calcium channel antagonist amlodipine in the treatment of acute alcoholic hepatitis. Journal of Hepatology 1998;28(2):194-8.
50. Cabré E, Rodríguez-Iglesias P, Caballería J, Quer JC, Sánchez-Lombrana JL, Parés A, et al. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology 2000;32:36-42.
51. Cabré E, Gassull MA. Metabolic and nutritional interventions in the treatment of alcoholic hepatitis. FALK Symposium 121. Steatohepatitis (NASH and ASH). Dordrecht/Boston/London: Kluwer Academic Publishers, 2001:305-16.
52. Chang TT, Lin CY, Chow NH, Hsu PI, Yang CC, Lin XZ, et al. Hepatitis B and hepatitis C virus infection among chronic alcoholic patients with liver disease in Taiwan. Journal of Formosan Medical Association 1994;93(2):128-33.
53. Christensen E, Gluud C. Glucocorticoids are inffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables. Gut 1995;37(1):113-8. [PMID: 7672658]
54. Moher D, Schulz KF, Altman DG for the CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. http://www.consort-statement.org/Statement/revisedstatement.htm (accessed 29 June 2006).
55. Corrao G, Zambon A, Torchio P, Arico S, La Vecchia C, di Iorio F. Attributable risk for symptomatic liver cirrhosis in Italy. Collaborative Groups for the Study of Liver Diseases in Italy. Journal of Hepatology 1998;28(4):608-14.
56. Demets DL. Pratical aspects in monitoring: a brief review. Statistics in Medicine 1987;6(7):753-60.
57. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
58. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315(7109):629-34. [PMID: 9310563]
59. Ferenchick GS. Anabolic/androgenic steroid abuse and thrombosis: is there a connection?. Medical Hypotheses 1991;35(1):27-31. [PMID: 1921773]
60. Flora K, Hahn M, Rosen H, Benner K. Milk thistle (Silybum marianum) for the therapy of liver disease. The American Journal of Gastroenterology 1998;93(2):139-43. [PMID: 9468229]
61. Gluud C, Bahsen M, Bennett P, Brodthagen UA, Dietrichson O, Johnsen SG, et al. Hypothalamic-pituitary-gonadal function in relation to liver function in men with alcoholic cirrhosis. Scandinavian Journal of Gastroenterology 1983;18:939-44.
62. Gluud C. Anabolic-androgenic steroid treatment of liver diseases. Liver 1984;4:159-69.
63. Gluud C, the Copenhagen Study Group for Liver Diseases. Serum testosterone concentrations in men with alcoholic liver cirrhosis: background for variation. Metabolism 1987;36:373-8.
64. Gluud C. Testosterone and alcoholic cirrhosis. Epidemiologic, pathophysiologic and therapeutic studies in men (Thesis). Danish Medical Bullettin 1988;35(6):564-75.
65. Gluud C. Steroid hormones and Budd-Chiari syndrome. Proceedings of the first international symposium on Budd-Chiari syndrome. September 10th-13th, Jinan, China, 1988:107-14.
66. Gluud C, Afroudakis A, Caballeria J, Laskus T, Morgan MY, Rueff B, et al. Diagnosis and treatment of alcoholic liver disease in Europe. Gastroenterology International 1993;6(4):221-30.
67. Gluud C. Alcoholic hepatitis: no glucocorticosteroids?. FALK Symposium 121. Steatohepatitis (NASH and ASH). Dordrecht/Boston/London: Kluwer Academic Publishers, 2001; Vol. 121:323-42.
68. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & sons, Ltd.
69. International conference on harmonisation expert working group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice. 1997 CFR & ICH Guidelines. 1. Vol. 1, PA 19063-2043, USA: Barnett International/PAREXEL, 1997.
70. Ioannidis JPA, Lau J. Evolution of treatment effects over time: empirical insigh from recursive cumulative metaanalyses. Proceedings of the National Academy of Sciences of the United States of America 2001;98:831-6.
71. Kjaergard LL, Villumsen J, Gluud C. Reported methological quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9. [MEDLINE: 11730399]
72. Koretz RL, Lipman TO, Klein S. AGA technical review on parenteral nutrition. Gastroenterology 2001;1214:970-1001.
73. Lewis JH, Tice HL, Zimmerman HJ. Budd-Chiari syndrome associated with oral contraceptive steroids. Review of treatment of 47 cases. Digestive Disease and Sciences 1983;28:673-83.
74. Liber CS. Alcoholic liver disease: new insights in pathogenesis lead to new treatments. Journal of Hepatology 2000;32(1 Suppl):113-28. [PMID: 10728799]
75. Lieber CS, Weiss DG, Groszmann R, Paronetto F, Schenker S. For the Veterans Affairs Cooperative Study 391 Group. II. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease. Alcohol Clinical and Experimental Research 2003;27:1765-72.
76. Marbet UA, Bianchi L, Meury U, Stalder GA. Long-term histological evaluation of the natural history and prognostic factors of alcoholic liver disease. Journal of Hepatology 1987;4(3):364-72.
77. Mato JM, Cámara J, Fernández de Paz J, Caballería L, Coll S, Caballero A, et al. S-Adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. Journal of Hepatology 1999;30:1081-9.
78. Mendenhall CL, Anderson S, Garcia-Pont P, Goldenberg S, Kiernan T, Seeff LB, et al. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. New England Journal of Medicine 1984;311(23):1464-70.
79. Mezey E, Caballeria J, Mitchell MC, Pares A, Herlong HF, Rodes J. Effect of parenteral amino acid supplementation on short-term and long-term outcomes in severe alcoholic hepatitis: a randomised controlled trial. Hepatology 1991;14(6):1090-6. [PMID: 1959859]
80. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses. Lancet 1998;352:609-13.
81. Morgan MY. Alcoholic liver disease: natural history, diagnosis, clinical features, evaluation, managment, prognosis, and prevention. In: Bircher J, Benhamou J-P, McIntyre N, Rizzetto M, Rodés J editor(s). Oxford Textbook of Clinical Hepatology. Second Edition. Vol. 2, Oxford: Oxford Medical Publications, 1999:1185-238.
82. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Annals of Internal Medicine 1992;116:78-84.
83. Powell WJ Jr, Klatskin G. Duration of survival in patients with Laennec´s cirrhosis. Influence of alcohol withdrawal, and possible effects of recent changes in general management of the disease. American Journal of Medicine 1968;44(3):406-20.
84. Poynard T, Barhelemy P, Fratte S, Boudjema K, Doffoel M, Vanlemmens C. Evaluation of efficacy of liver transplantation in alcoholic cirrhosis by a case-control study and simulated control. The Lancet 1994;344(8921):502-7.
85. Purhoit V, Brenner DA. Mechanisms of alcohol-induced hepatic fibrosis: a summary of the Ron Thurman Symposium. Hepatology 2006;43:872-8.
86. Rambaldi A, Gluud C. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. The Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No.: CD002148. DOI: 10.1002/14651858.CD002148.pub2.
87. Rambaldi A, Jacobs BP, Iaquinto G, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. The Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No.: CD003620. DOI: 10.1002/14651858.CD003620.pub2.
88. Rambaldi A, Gluud C. Propylthiouracil for alcoholic liver disease. The Cochrane Database of Systematic Reviews 2005, Issue 4. Art. No.: CD002800. DOI: 10.1002/14651858.CD002800.pub2.
89. Rambaldi A, Gluud C. S-adenosyl-L-methionine for alcoholic liver diseases. The Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No.: CD002235. DOI: 10.1002/14651858.CD002235.pub2.
90. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 4.2 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2003.
91. Rubin E, Lieber CS. Alcohol-induced hepatic injury in nonalcoholic volunteers. New England Journal of Medicine 1968;278(16):869-76.
92. Schulz KF, Chalmers I, Haeys RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Journal of American Medical Association 1995;273(5):408-12. [PMID: 7823387]
93. Shahidi NT. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clinical Therapeutics 2001;23:1355-90.
94. Sørensen TIA, Orholm M, Bentsen KD, Høybye G, Eghøje K, Christoffersen P. Prospective evaluation of alcohol abuse and alcoholic liver injury in men as predictors of developement of cirrhosis. Lancet 1984;2(8397):241-4.
95. Tamburro C, Leevy CM. Protein clotting factor synthesis in liver disease. Gastroenterology 1967;52:325.
96. Trinchet JC, Balkau B, Poupon RE, Heintzmann F, Callard P, Gotheil C, et al. Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon: a multicenter sequential trial. Hepatology 1992;15(1):76-81. [PMID: 1727803]
97. Van Steenbergen W. Alcohol, liver cirrhosis, and disorders in sex hormone metabolism [Alcohol, levercirrhose, en stoornissen in het metabolisme van de geslachtshormonen]. Acta Clinica Belgica 1993;48(4):269-83. [PMID 8212979]
98. Vickers A, Goyal N, Harland R, Rees R. Do certain countries produce only positive results? A systematic review of controlled trials. Controlled Clinical Trials 1998;19(2):159-66. [PMID: 9551280]
99. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomised clinical trials. Journal of American Medical Association 1991;266:93-8.
100. Rambaldi A, Iaquinto G, Gluud C. Anabolic-androgenic steroids for alcoholic liver disease: a Cochrane review. The American Journal of Gastroenterology 2002;97(7):1674-81.
101. Rambaldi A, Iaquinto G, Gluud C. Anabolic-androgenic steroids for alcoholic liver disease. The Cochrane Database of Systematic Reviews 2003, Issue 1. Art. No.: CD003045. DOI: 10.1002/14651858.CD003045.